header
Image from OpenLibrary

Molecular markers in advanced non small cell lung cancer patients receiving gemcitabine and cisplatin / Maha Yahia Ismailc ; Supervised Rabab Mohamed Gaafar , Abeer Ahmed Bahnasy , Maha Hussin Helal

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Maha Yahia Ismail , 2015Description: 192 P. ; 25cmOther title:
  • قياس معدل الدلالات الجزيئية لدى مرضى سرطان الرئة المتقدم الذين يعالجون بإستخدام الجمسيتبين و السيسبلاتين [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Medical Oncology Summary: Despite the standard treatment for advanced NSCLC, the overall prognosis is very poor. Using molecular markers as a predictor for chemotherapy response is an important area of research. From Jan 2011 to Jan 2014, we conducted a prospective study on 85 chemotherapy naive patients with advanced stage NSCLC. ERCC1, BRCA1 and RRM1 proteins level in blood samples by ELISA and mRNA expression in paraffin embedded tumor tissues were detected. All patients received gemcitabine and cisplatin. Assessment of molecular expression, correlation with response, TTP and OS were done. 71patients were evaluable for response. 43.3% of patients with high ERCC1 mRNA expression were non responders (PD); in contrary 73.2 % of ERCC1 negative patients had clinical benefit (PR or SD). Patients with high ERCC1 expression had shorter TTP (P = 0.001) and OS (P = 0.022), Patients with low RRM1 expression had longer OS (P = 0.052). No correlation between the BRCA1 expression and both the response and survival were found.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.Ph.D.2015.Ma.M (Browse shelf(Opens below)) Not for loan 01010110066258000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.04.Ph.D.2015.Ma.M (Browse shelf(Opens below)) 66258.CD Not for loan 01020110066258000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Medical Oncology

Despite the standard treatment for advanced NSCLC, the overall prognosis is very poor. Using molecular markers as a predictor for chemotherapy response is an important area of research. From Jan 2011 to Jan 2014, we conducted a prospective study on 85 chemotherapy naive patients with advanced stage NSCLC. ERCC1, BRCA1 and RRM1 proteins level in blood samples by ELISA and mRNA expression in paraffin embedded tumor tissues were detected. All patients received gemcitabine and cisplatin. Assessment of molecular expression, correlation with response, TTP and OS were done. 71patients were evaluable for response. 43.3% of patients with high ERCC1 mRNA expression were non responders (PD); in contrary 73.2 % of ERCC1 negative patients had clinical benefit (PR or SD). Patients with high ERCC1 expression had shorter TTP (P = 0.001) and OS (P = 0.022), Patients with low RRM1 expression had longer OS (P = 0.052). No correlation between the BRCA1 expression and both the response and survival were found.

Issued also as CD

There are no comments on this title.

to post a comment.